ScholarLens Back to search
2017•American Journal of HematologyOpen access

Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)

Sophie Godet, Caroline A. Protin, Jehan Dupuis, Caroline Dartigeas, Jean Bastié, Charles Herbaux, Véronique Leblond, Sophie de Guibert, David Ghez, Annie Brion, Loïc Ysebaert, Alain Jacques Delmer, Anne Quinquenel

Open full text 4 citations

Abstract

patient choice, with physician advice, of either supportive care or lowdose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Open-access reader

About this research paper

What this paper is about

patient choice, with physician advice, of either supportive care or lowdose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

patient choice, with physician advice, of either supportive care or lowdose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Key concepts: Ibrutinib, Idelalisib, Ofatumumab, Discontinuation, Medicine, Chronic lymphocytic leukemia, Internal medicine, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO) — Research Paper | ScholarLens